Sunshine Biopharma Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Adva-27a is Sunshine Biopharma's flagship anticancer compound, a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells. These and other preclinical results have been Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012. Adva-27a is currently in the IND-Enabling stage of development. We are planning to conduct our Adva-27a Phase I Clinical Trials on Pancreatic Cancer and in parallel multidrug resistant Breast Cancer patients at McGill University's Jewish General Hospital in Montreal (Canada).
The US Patent Number 8,236,935 covering Adva-27a was issued on August 7, 2012. Sunshine Biopharma is direct owner of this as well as all right, title and interest in and to all worldwide patents covering Adva-27a, including all issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029. Sunshine Biopharma has not granted any licenses or rights to any entity under these patents.
In addition, Sunshine Biopharma has other anticancer drugs currently on the market. lease see Drugs on the Market.
© 2009 - 2016 Sunshine Biopharma Inc., All Rights Reserved.